A new study published in Addiction has found that cytisine, a low-cost, generic stop-smoking aid that has been used in eastern Europe since the 1960s, increases the chances of successful smoking cessation by more than two-fold compared with placebo and may be more effective than nicotine replacement therapy. It has a benign safety profile, with no evidence of serious safety concerns.
Bausch + Lomb bulks up OTC business with J&J deal
Dive Brief: Bausch + Lomb continues to bulk up via dealmaking, announcing Thursday a deal to buy a line of eye and contact lens drops